If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
102
results.
Updated on
20/08/2026 [07:13:00]
Absstract of: PL451191A1
Przedmiotem zgłoszenia jest liposomowy preparat, do stosowania w leczeniu COVID-19.
Absstract of: US20260234224A1
The present disclosure relates to antibodies and uses thereof for treating, preventing, and detecting coronavirus infection.
Absstract of: US20260235601A1
0000 The present invention relates to development of novel ssDNA aptamers comprising the oligonucleotide sequence that detect receptor-binding domain (RBD) of Severe Acute Respiratory Syndrome Corona virus (SARS-nCOV-2) infection. The ssDNA aptamers of the present invention may be used in lateral flow assays, electrochemical sensors and calorimetric sensors using gold nanoparticles. The present invention also relates to an analytical composition comprising said ssDNA aptamers. Further, the present invention also relates to a diagnostic kit for detecting RBD of SARS-nCoV-2.
Absstract of: US20260234629A1
0000 The present invention relates to a new antisense oligonucleotide, a pharmaceutical composition comprising it and their use for preventing or treating infection by coronavirus, especially by SARS-CoV-2 virus which causes the infection disease COVID-19.
Absstract of: US20260234221A1
The disclosure relates to a pharmaceutical composition comprising human plasma-derived polyclonal, anti-SARS-CoV-2 hyperimmune globulins and to said pharmaceutical composition for use in the treatment of a SARS-CoV-2 Omicron variant infection. The disclosure also relates to a method for the preparation of a polyclonal, hyperimmune globulin composition anti-SARS-CoV-2.
Absstract of: US20260234220A1
0000 The present invention provides neutralizing monoclonal antibodies targeting the spike protein of Sarbecoviruses, such as Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-1 or SARS-CoV-2 like COVID-19). The monoclonal antibodies of the invention can inhibit or neutralize SARS-CoV-1 or SARS-CoV-2 activity and advantageously be used for treating, preventing or diagnosing COVID-19 infection in humans due to their significant cross-reactivity among SARS-CoV-2 variants.
Absstract of: US20260234738A1
0000 The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
Absstract of: US20260232749A1
A polyphenol-rich composition is orally administered to alleviate a sign or symptom of a post-viral syndrome, and preferably post-COVID syndrome. Most typically, the composition comprises at least 50 wt % total catechins, at least 20 wt % total chlorogenic acids, and optionally up to 30 wt % total supplemental antioxidants. The composition may be formulated from a green coffee bean extract, a green tea extract, a turmeric extract, a tart cherry or extract thereof, a broccoli or extract thereof, and a kale or extract thereof. Notably, such compositions were effective in individuals post SARS-CoV2 infection to reduce proinflammatory cytokines and interleukins, increase NOHb, and to reduce reactive oxygen species due to mitochondrial dysfunction, iNOS activity, and NOX2 activity.
Absstract of: WO2026165666A1
The present disclosure provides a method for treating long CO VID ( e.g., severe long CO VID) or at least one symptom thereof in a subpopulation of subjects displaying a combination of biomarkers namely a blood level of secreted B-cell activating factor and of membrane BAFF in white blood cells higher than a corresponding reference level; and at least one of blood level of precursor- like marginal zone B-cell populations, zonulin, anti-Mi-2 nuclear antigen autoantibodies, anti-SmD autoantibodies, anti-Ul-snRNP-A autoantibodies, anti-RCN2 autoantibodies, lipopolysaccharide-binding protein (LBP), and p-D-glucan higher than a corresponding reference level, and APRIL lower than a corresponding reference level, comprising administering a therapeutically effective amount of a BAFF inhibitor to the subject. It also provides a method of diagnosing a subject as having long CO VID using the combination of biomarkers and a diagnosis kit comprising ligands for the biomarkers.
Absstract of: US20260232759A1
Anti-SARS-CoV-2 α/β-polypeptides, pharmaceutical compositions containing the same, and methods to inhibit, treat, and ameliorate SARS-CoV-2 infections in mammals, including humans.
Absstract of: WO2026165610A1
The present invention relates to a pharmaceutical composition comprising the lipopeptide adjuvant Cys-Dipalmitoyl-Ser-Lys-Lys-Lys-Lys-PEG2-NH2 (otherwise referred to as dipalmitoyl- S-glyceryl-cysteine or Pam2Cys), an antigen, and mannitol, for the treatment and/or prevention of respiratory infections. Disclosed herein, is NoVCoV, a nasal dry powder vaccine that provides a novel and stable alternative to traditional liquid vaccines. This formulation is not only effective for preventing and/or treating COVID-19 but is also adaptable for addressing other respiratory infections.
Absstract of: US20260232725A1
0000 This invention provides a method for the therapeutic inhalation of hypochlorous acid (HOCl) to treat respiratory infections, reduce lung inflammation, and eliminate airborne pathogens in humans and animals. It describes controlled delivery of HOCl (10-50 ppm) via nebulizers, humidifiers, CPAP devices, ventilators, and direct tracheal instillation to improve oxygenation, break down mucus, and prevent secondary infections. The stabilized HOCl formulation ensures safety and efficacy, distinguishing it from surface disinfection applications. The method leverages HOCl's natural antimicrobial, anti-inflammatory, and mucolytic properties for direct respiratory treatment without toxicity or lung irritation. Applications include treating pneumonia, COVID-19, asthma, bronchitis, and ventilator-associated infections, as well as reducing airborne pathogen transmission in enclosed spaces. The invention presents a novel, non-toxic, and cost-effective approach to respiratory care, enhancing both individual treatment and public health disease mitigation.
Absstract of: US20260234196A1
Disclosed in the present invention are a polypeptide and a polypeptide composition specifically binding to a SARS-CoV-2 spike protein, and preparation methods and the uses thereof. By means of binding to S1 protein, the polypeptide and the polypeptide composition can block the binding of SARS-CoV-2 virus to a key target protein angiotensin-converting enzyme 2 (ACE2) protein on the surface of a host cell thereof, thereby providing a feasible targeting drug for the treatment of Coronavirus disease 2019.
Absstract of: WO2026169917A1
Provided are engineered SARS-CoV-2 virus-like particles (VLPs) and methods of making and using the VLPs for mRNA delivery. A 3 plasmid (3P) VLP system displays ~7-fold higher viral entry efficiency compared to VLPs formed by co-transfection with 4 plasmids. A 2 plasmid (2P) VLP system is provided where one vector carries the viral surface glycoprotein and the second carries the remaining SARS-CoV-2 structural proteins and reporter gene. The VLPs can carry up to four transgenes, including functional Cas9 mRNA for genome editing. Gene editing of specific target cell types is performed modifying VLP tropism. Successful mRNA delivery to mouse lungs shows that the SARS-CoV-2 VLPs can overcome natural biological barriers to enable pulmonary gene delivery.
Absstract of: WO2025073771A1
The present invention inter alia relates to an use of an isolated polypeptide or an antigenic fragment thereof, comprising a polypeptide region having at least 60% sequence identity with any one of the polypeptide sequences selected from the group consisting of SEQ ID No.: 1-11, 16-20 and 23-28; wherein the isolated polypeptide is having a length of no more than 200 contiguous amino acids for diagnosing Long COVID or Post-Vac-Syndrome, or for predicting a risk of developing Long COVID or Post-Vac-Syndrome. The present invention also relates to the isolated polypeptide or antigenic fragment thereof for use in preventing, treating or ameliorating Long COVID or Post-Vac-Syndrome., as well as to a method of detecting a presence of antibodies against SARS-CoV-2 in a subject, comprising the step of contacting a sample of said subject with at least one of the polypeptide or antigenic fragment thereof.
Absstract of: EP4790065A1
Coronavirus spike protein variants for use in antigens for vaccines for coronavirus infection are provided.A coronavirus spike protein variant comprising:(a) a receptor binding domain (RBD) consisting of an amino acid sequence set forth in SEQ ID NO: 1;(b) an RBD consisting of an amino acid sequence obtained by substituting, deleting, inserting, or adding one to several amino acids in the amino acid sequence set forth in SEQ ID NO: 1, and having neutralizing antibody-inducing activity against SARS-CoV-2 and SARS-CoV-1 equivalent to that of an RBD consisting of the amino acid sequence set forth in SEQ ID NO: 1; or(c) an RBD consisting of an amino acid sequence that has at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1, and having neutralizing antibody-inducing activity against SARS-CoV-2 and SARS-CoV-1 equivalent to that of the RBD consisting of the amino acid sequence set forth in SEQ ID NO: 1.
Absstract of: US20260226034A1
0000 Methods and compositions for treating SARS-CoV-2 and COVID-19 are disclosed. Sulfone-1H-pyrrole-2-carboxamides of the following formula
0000
0000 inhibit the SARS-CoV-2 PLpro/NSP3 protein and are therefore useful for treating SARS-CoV-2 and COVID-19.
Absstract of: US20260226425A1
An isolated nucleic acid comprising a recombinant coronavirus genome having a genetic modification that provides cold-adapted growth relative to a parent virus that is not cold-adapted and a vaccine comprising the recombinant genome and methods of using the vaccine are provided.
Absstract of: US20260226140A1
Disclosed are a monoclonal antibody capable of rapidly, simply, and highly sensitively detecting and measuring SARS-CoV-2 contained in a test sample, and an immunoassay method and immunoassay device for SARS-CoV-2 using the same. The monoclonal antibody or its antigen-binding fragment includes heavy chain CDR1-CDR3 having specific amino acid sequences and light chain CDR1-CDR3 having specific amino acid sequences. The immunoassay method for SARS-CoV-2 includes performing an immunoassay of SARS-CoV-2 utilizing an antigen-antibody reaction between this monoclonal antibody or its antigen-binding fragment and SARS-CoV-2 in a sample.
Absstract of: US20260227401A1
Disclosed is a high performance anti-SARS-CoV-2 antibody and a detection reagent using it. The method of detecting SARS-CoV-2 includes detecting SARS-CoV-2 in a sample by an immunoassay method using a monoclonal antibody that specifically reacts with the N protein of SARS-CoV-2, or an antigen-binding fragment thereof. The detection kit for SARS-CoV-2 includes a monoclonal antibody that specifically reacts with the N protein of SARS-CoV-2, or an antigen-binding fragment thereof.
Absstract of: US20260227400A1
0000 Disclosed is a high performance anti-SARS-CoV-2 antibody and a detection reagent using it. The method of detecting SARS-CoV-2 includes detecting SARS-CoV-2 in a sample by an immunoassay method using a monoclonal antibody that specifically reacts with 301aa-319aa, 301aa-320aa, or 351aa-375aa of the amino acid sequence of the N protein of SARS-CoV-2, or an antigen-binding fragment thereof. The detection kit for SARS-CoV-2 includes a monoclonal antibody that specifically reacts with 301aa-319aa, 301aa-320aa, or 351aa-375aa of the amino acid sequence of the N protein of SARS-CoV-2, or an antigen-binding fragment thereof.
Absstract of: US20260227402A1
0000 Disclosed is a high-performance anti-SARS-CoV-2 antibody and a detection reagent using it. The method of detecting SARS-CoV-2 includes detecting SARS-CoV-2 in a sample by an immunoassay method using a monoclonal antibody that specifically reacts with the RNA-binding domain in the N protein of SARS-CoV-2, or an antigen-binding fragment thereof. The detection kit for SARS-CoV-2 includes a monoclonal antibody that specifically reacts with the RNA-binding domain in the N protein of SARS-CoV-2, or an antigen-binding fragment thereof.
Absstract of: AU2025218930A1
The present disclosure relates to compounds of Formula I and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
Absstract of: WO2026165023A1
The present disclosure is directed to antibodies binding to and neutralizing Middle East Respiratory Syndrome-Related Coronavirus (MERS-CoV) and methods for use thereof.
Nº publicación: WO2026163027A1 06/08/2026
Applicant:
UNIV OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION [US]
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Absstract of: WO2026163027A1
Provided herein is a replication-defective coronavirus having in its genome a modification, wherein the modification results in a reduced expression of the M gene compared to a coronavirus lacking the modification.
BOPI
Electronic site
